LifeVantage 향후 성장
Future 기준 점검 0/6
LifeVantage 의 수익과 수익은 각각 연간 6.4% 및 10.7% 감소할 것으로 예상됩니다 while EPS는 연간 10.8% 만큼 쇠퇴할 것으로 예상됩니다.
핵심 정보
-10.7%
이익 성장률
-10.81%
EPS 성장률
| Personal Products 이익 성장 | 32.2% |
| 매출 성장률 | -6.4% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 13 May 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Jun 24
LFVN: Downgrade And Softer Guidance Will Set Up Portugal Expansion Upside
Analysts have trimmed their price target on LifeVantage to $7.00, reflecting a modestly higher discount rate and slightly adjusted P/E assumptions following the latest downgrade in Street research. What’s in the News for LifeVantage LifeVantage updated earnings guidance for the fiscal year ending June 30, 2026, indicating that fiscal 2026 revenue is expected to be close to the lower end of the previously issued guidance range.내러티브 업데이트 • Jun 08
LFVN: Downgrade And Softer Guidance Will Limit Portugal Expansion Support
Analysts have reduced their fair value estimate for LifeVantage after a recent downgrade in Street research coverage, reflecting a slightly lower discount rate and modestly adjusted expectations for revenue trends, profit margins, and future P/E multiples. What's in the News LifeVantage updated guidance for the fiscal year ending June 30, 2026, and now expects revenue to be close to the lower end of its previously issued range.내러티브 업데이트 • May 17
LFVN: Reset Expectations And Portugal Expansion Will Support Future Upside Potential
Analysts cut their price target on LifeVantage from $8 to $7, reflecting a lower fair value estimate, softer profit margin assumptions, and a higher future P/E, following the recent downgrade highlighted in Street research. Analyst Commentary Recent Street commentary points to a more cautious stance on LifeVantage, with the lower price target tied to reassessed earnings power and valuation assumptions following the downgrade.내러티브 업데이트 • May 01
LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential
Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.내러티브 업데이트 • Apr 17
LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.내러티브 업데이트 • Apr 02
LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.내러티브 업데이트 • Mar 19
LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.내러티브 업데이트 • Mar 05
LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential
Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.내러티브 업데이트 • Feb 18
LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential
Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.분석 기사 • Feb 06
Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 26% in the last...내러티브 업데이트 • Feb 04
LFVN: Gut Health Research Progress Will Support Confident Upside Potential
Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).내러티브 업데이트 • Jan 21
LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential
Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).내러티브 업데이트 • Jan 07
LFVN: Gut Study Progress Will Drive Future Upside Potential
Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).내러티브 업데이트 • Dec 22
LFVN: Future Gut Health Research And Buybacks Will Drive Upside
Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.내러티브 업데이트 • Dec 08
LFVN: Future Index Inclusion Will Drive Upside Potential
Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).내러티브 업데이트 • Nov 24
LFVN: Share Repurchases and New Index Addition Will Drive Value
LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.분석 기사 • Nov 14
Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 28% in the last...분석 기사 • Nov 04
We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...분석 기사 • Sep 30
It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks
LifeVantage Corporation ( NASDAQ:LFVN ) shareholders that were waiting for something to happen have been dealt a blow...분석 기사 • Sep 05
LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045
The board of LifeVantage Corporation ( NASDAQ:LFVN ) has announced that it will pay a dividend on the 16th of...Seeking Alpha • Jul 21
The LifeVantage Advantage: High Retention, High Returns
Summary LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN’s growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream. Shares trade at a discounted 15.6x forward P/E, below the staples sector median and peers like Nature’s Sunshine, offering valuation upside, alongside dividend yield and liquidity strength. Risks include heavy reliance on one product and retention uncertainty, as subscription fatigue, or competitive GLP-1 alternatives could weaken revenue durability and challenge the bullish case. Read the full article on Seeking Alpha분석 기사 • May 13
Shareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality
When companies post strong earnings, the stock generally performs well, just like LifeVantage Corporation's...분석 기사 • May 02
What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash
To the annoyance of some shareholders, LifeVantage Corporation ( NASDAQ:LFVN ) shares are down a considerable 26% in...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 6/30/2028 | 165 | 4 | N/A | N/A | 1 |
| 6/30/2027 | 178 | 5 | 11 | 16 | 3 |
| 6/30/2026 | 184 | 5 | 7 | 15 | 3 |
| 3/31/2026 | 195 | 6 | 4 | 7 | N/A |
| 12/31/2025 | 210 | 8 | 2 | 4 | N/A |
| 9/30/2025 | 229 | 10 | 9 | 10 | N/A |
| 6/30/2025 | 229 | 10 | 11 | 12 | N/A |
| 3/31/2025 | 222 | 9 | 12 | 13 | N/A |
| 12/31/2024 | 212 | 7 | 13 | 14 | N/A |
| 9/30/2024 | 196 | 4 | 5 | 7 | N/A |
| 6/30/2024 | 200 | 3 | 10 | 12 | N/A |
| 3/31/2024 | 205 | 4 | 11 | 13 | N/A |
| 12/31/2023 | 211 | 3 | 11 | 14 | N/A |
| 9/30/2023 | 213 | 3 | 9 | 13 | N/A |
| 6/30/2023 | 213 | 3 | 4 | 7 | N/A |
| 3/31/2023 | 210 | -1 | 3 | 6 | N/A |
| 12/31/2022 | 206 | -1 | 1 | 3 | N/A |
| 9/30/2022 | 205 | 0 | 4 | 6 | N/A |
| 6/30/2022 | 206 | 3 | 6 | 8 | N/A |
| 3/31/2022 | 210 | 9 | 12 | 14 | N/A |
| 12/31/2021 | 212 | 10 | 13 | 16 | N/A |
| 9/30/2021 | 219 | 14 | 15 | 18 | N/A |
| 6/30/2021 | 220 | 13 | 13 | 16 | N/A |
| 3/31/2021 | 225 | 12 | 13 | 17 | N/A |
| 12/31/2020 | 229 | 12 | 15 | 17 | N/A |
| 9/30/2020 | 232 | 12 | 18 | 21 | N/A |
| 6/30/2020 | 233 | 12 | 16 | 18 | N/A |
| 3/31/2020 | 230 | 12 | 13 | 16 | N/A |
| 12/31/2019 | 230 | 12 | N/A | 17 | N/A |
| 9/30/2019 | 227 | 8 | N/A | 12 | N/A |
| 6/30/2019 | 226 | 7 | N/A | 18 | N/A |
| 3/31/2019 | 224 | 7 | N/A | 16 | N/A |
| 12/31/2018 | 218 | 6 | N/A | 16 | N/A |
| 9/30/2018 | 210 | 6 | N/A | 13 | N/A |
| 6/30/2018 | 203 | 6 | N/A | 13 | N/A |
| 3/31/2018 | 200 | 3 | N/A | 10 | N/A |
| 12/31/2017 | 194 | 1 | N/A | 6 | N/A |
| 9/30/2017 | 194 | 1 | N/A | 6 | N/A |
| 6/30/2017 | 199 | 2 | N/A | 7 | N/A |
| 3/31/2017 | 202 | 4 | N/A | 4 | N/A |
| 12/31/2016 | 213 | 5 | N/A | 3 | N/A |
| 9/30/2016 | 216 | 6 | N/A | 6 | N/A |
| 6/30/2016 | 207 | 6 | N/A | 6 | N/A |
| 3/31/2016 | 199 | 4 | N/A | 10 | N/A |
| 12/31/2015 | 188 | 3 | N/A | 14 | N/A |
| 9/30/2015 | 184 | 3 | N/A | 11 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: LFVN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -10.7%).
수익 vs 시장: LFVN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -10.7%).
고성장 수익: LFVN 의 수익은 향후 3년간 감소할 것으로 예상됩니다.
수익 대 시장: LFVN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -6.4%).
고성장 매출: LFVN 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -6.4%).
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: LFVN의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/30 11:16 |
| 종가 | 2026/06/29 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/06/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
LifeVantage Corporation는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Mitchell Pinheiro | Imperial Capital |
| Ryan Meyers | Lake Street Capital Markets, LLC |